Stocks Overview

LAST PRICE
38.4600
TODAY'S CHANGE (%)
Trending Down-1.2300 (-3.0990%)

Bid / Lots
38.5700/ 2
Ask / Lots
40.8000/ 1
Open / Previous Close
39.4400 / 39.6900
Day Range
Low 38.2100
High 39.4400
52 Week Range
Low 38.2100
High 76.9800
Volume
684,351
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Thursday's close: 39.69
Time	Volume	IMCR
09:32 ET	1801	39.1
09:34 ET	400	39.32
09:41 ET	671	39.02
09:43 ET	462	38.855
09:48 ET	181	38.855
09:50 ET	5823	38.75
09:52 ET	1184	38.65
09:54 ET	491	38.775
09:56 ET	100	38.76
09:59 ET	200	38.73
10:01 ET	1600	38.825
10:08 ET	100	38.745
10:10 ET	200	38.69
10:12 ET	212	38.8
10:15 ET	100	38.81
10:17 ET	100	38.96
10:19 ET	9264	38.71
10:21 ET	4509	38.63
10:24 ET	600	38.6699
10:26 ET	800	38.67
10:28 ET	563	38.82
10:30 ET	467	38.87
10:35 ET	659	38.735
10:39 ET	100	38.78
10:42 ET	100	38.68
10:46 ET	100	38.69
10:53 ET	300	38.67
10:55 ET	234	38.624
11:00 ET	1662	38.6
11:02 ET	100	38.56
11:04 ET	100	38.55
11:08 ET	490	38.53
11:13 ET	1493	38.635
11:20 ET	100	38.71
11:22 ET	100	38.66
11:26 ET	200	38.73
11:27 ET	200	38.805
11:29 ET	528	38.83
11:36 ET	406	38.73
11:38 ET	100	38.63
11:40 ET	100	38.58
11:42 ET	600	38.52
11:44 ET	13586	38.57
11:45 ET	200	38.55
11:47 ET	100	38.52
11:49 ET	100	38.55
11:51 ET	300	38.61
11:56 ET	100	38.545
12:02 ET	400	38.55
12:07 ET	100	38.575
12:09 ET	100	38.62
12:12 ET	930	38.67
12:18 ET	401	38.725
12:20 ET	300	38.64
12:21 ET	200	38.64
12:23 ET	100	38.56
12:25 ET	100	38.64
12:27 ET	100	38.58
12:30 ET	700	38.54
12:32 ET	100	38.545
12:34 ET	4695	38.685
12:38 ET	1300	38.575
12:41 ET	271	38.57
12:43 ET	100	38.55
12:48 ET	350	38.57
12:52 ET	8588	38.33
12:54 ET	1900	38.345
12:56 ET	400	38.32
12:57 ET	915	38.275
12:59 ET	600	38.22
01:01 ET	20612	38.43
01:03 ET	700	38.435
01:06 ET	28629	38.56
01:08 ET	11500	38.635
01:10 ET	7691	38.635
01:12 ET	813	38.55
01:14 ET	100	38.5
01:15 ET	500	38.525
01:17 ET	500	38.46
01:19 ET	349	38.4
01:24 ET	200	38.38
01:26 ET	800	38.46
01:28 ET	1311	38.5
01:30 ET	200	38.54
01:32 ET	100	38.505
01:33 ET	100	38.505
01:35 ET	740	38.49
01:37 ET	300	38.49
01:39 ET	2222	38.53
01:42 ET	215	38.57
01:44 ET	558	38.67
01:48 ET	502	38.67
01:50 ET	1391	38.63
01:51 ET	200	38.595
01:53 ET	100	38.57
01:55 ET	739	38.57
01:57 ET	300	38.53
02:00 ET	400	38.46
02:02 ET	100	38.46
02:04 ET	100	38.485
02:06 ET	400	38.51
02:08 ET	200	38.5
02:09 ET	100	38.51
02:11 ET	1663	38.57
02:15 ET	547	38.58
02:18 ET	536	38.605
02:20 ET	200	38.605
02:22 ET	100	38.58
02:24 ET	200	38.64
02:26 ET	300	38.615
02:27 ET	959	38.68
02:29 ET	400	38.665
02:31 ET	200	38.67
02:33 ET	101	38.68
02:36 ET	650	38.68
02:38 ET	4394	38.71
02:40 ET	864	38.7001
02:42 ET	22020	38.695
02:44 ET	100	38.68
02:45 ET	780	38.695
02:47 ET	100	38.695
02:49 ET	1707	38.655
02:51 ET	898	38.68
02:54 ET	100	38.69
02:56 ET	300	38.7
02:58 ET	11369	38.78
03:00 ET	100	38.74
03:02 ET	4221	38.84
03:03 ET	2266	38.79
03:09 ET	57056	38.845
03:12 ET	200	38.83
03:14 ET	100	38.835
03:16 ET	200	38.83
03:18 ET	10600	38.87
03:20 ET	300	38.9
03:21 ET	850	38.9
03:23 ET	2655	38.74
03:25 ET	112	38.63
03:27 ET	14235	38.88
03:30 ET	900	38.69
03:32 ET	715	38.8
03:34 ET	612	38.81
03:36 ET	200	38.88
03:38 ET	200	38.89
03:39 ET	1040	39.01
03:41 ET	1000	38.89
03:43 ET	910	38.87
03:45 ET	2103	38.9
03:50 ET	1458	38.95
03:52 ET	1757	38.87
03:54 ET	2600	38.92
03:56 ET	6010	38.74
03:57 ET	11922	38.6
03:59 ET	59197	38.46

Data delayed at least 15 minutes.

Jun 5, 2024
- DJ Immunocore Holdings Price Target Maintained With a $100.00/Share by HC Wainwright & Co., from 11:45AM ET on Wednesday Jun 05, 2024 by Dow Jones
  11:45AM ET on Wednesday Jun 05, 2024 by Dow Jones
Jun 3, 2024
- DJ Immunocore Holdings Price Target Maintained With a $81.00/Share by Needham, from 6:31AM ET on Monday Jun 03, 2024 by Dow Jones
  6:31AM ET on Monday Jun 03, 2024 by Dow Jones
Jun 1, 2024
- Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response, from 8:00AM ET on Saturday Jun 01, 2024 by Dow Jones
  8:00AM ET on Saturday Jun 01, 2024 by Dow Jones
May 31, 2024
- Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024, from 4:05PM ET on Friday May 31, 2024 by Dow Jones
  4:05PM ET on Friday May 31, 2024 by Dow Jones
May 30, 2024
- Immunocore to present at the Jefferies Global Healthcare Conference, from 4:00PM ET on Thursday May 30, 2024 by Dow Jones
  4:00PM ET on Thursday May 30, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesIMCR Immunocore Holdings PLC	2.0B	-32.1x	---
United StatesLGND Ligand Pharmaceuticals Inc	1.4B	15.3x	-12.71%
United StatesINVA Innoviva Inc	992.9M	7.3x	-9.89%
United StatesEOLS Evolus Inc	721.9M	-10.8x	---
United StatesAVDL Avadel Pharmaceuticals PLC	1.5B	-8.5x	---
United StatesANIP ANI Pharmaceuticals Inc	1.3B	39.3x	-8.16%
As of 2024-06-15

Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.

Contact Information

Headquarters: 90 Park Drive, Milton Park, AbingdonABINGDON, United Kingdom OX14 4RY
Phone: 123-543-8600
Fax: ---

Executives

Independent Chairman of the Board: John Bell
Chief Executive Officer, Director: Bahija Jallal
Chief Financial Officer, Head of Strategy: Brian Di Donato
Chief Human Resource Officer: Tina St Leger
Head of Research and Development: David Berman

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$2.0B
Revenue (TTM)	$265.8M
Shares Outstanding	50.0M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	0.79
EPS	$-1.20
Book Value	$7.42
P/E Ratio	-32.1x
Price/Sales (TTM)	7.5
Price/Cash Flow (TTM)	---
Operating Margin	-24.46%

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Immunocore Holdings PLC
NASDAQ:IMCRUnited States

Search Criteria

Charts

Recent News

Jun 5, 2024

DJ Immunocore Holdings Price Target Maintained With a $100.00/Share by HC Wainwright & Co., from 11:45AM ET on Wednesday Jun 05, 2024 by Dow Jones

Jun 3, 2024

DJ Immunocore Holdings Price Target Maintained With a $81.00/Share by Needham, from 6:31AM ET on Monday Jun 03, 2024 by Dow Jones

Jun 1, 2024

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response, from 8:00AM ET on Saturday Jun 01, 2024 by Dow Jones

May 31, 2024

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024, from 4:05PM ET on Friday May 31, 2024 by Dow Jones

May 30, 2024

Immunocore to present at the Jefferies Global Healthcare Conference, from 4:00PM ET on Thursday May 30, 2024 by Dow Jones

Pharmaceuticals - Diversified Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar